Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-CAR4BRAIN in Pediatric DIPG, DMG, and Recurrent/Refractory CNS Tumors
NCT05768880Phase 1Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- May 2023
- Primary completion
- Jan 2028
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of SC-CAR4BRAIN in diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG) and central nervous system tumor (2 arms), sponsored by Seattle Children's. Primary endpoints: Manufacturing Feasibility at 42 days, Safety of SC-CAR4BRAIN and 2 more. Started May 2023; status: active, not recruiting.
02
Drugs
SC-CAR4BRAIN
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)central nervous system tumor
Beyond the preview
Go deeper on NCT05768880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768880.